Results 121 to 130 of about 44,768 (301)

IRF4 regulates myeloid-derived suppressor cells expansion and function in Schistosoma japonicum-infected mice

Parasites & Vectors
Background Interferon regulatory factor 4 (IRF4) is a crucial member of the IRF family of transcription factors and is pivotal in orchestrating the body’s defense against tumors and infections by modulating the differentiation and functionality of immune
Lu Zhou, Peibin Lin, Guorong Deng, Lengshan Mo, Cansheng Hong, Zhihan Jiang, Yiqiang Zhu, Yi Zhao, Yanwei Qi, Tengfei Hu, Qianlian Wu, Jian Zhang, Qingqing Li, Quan Yang   +13 more
doaj   +1 more source

Interactions between glioblastoma and myeloid cells

Frontiers in Cell and Developmental Biology
Standing as the most aggressive form of primary malignant tumor, Glioblastoma (GBM) tumors with marked heterogeneity represents one of the enormous challenges in glioma treatment.
Yuting Li, Yuting Li, Yuhong Chen, Kai Cai, Kai Cai, Yujuan Qin, Xi Wang, Bo Zhang, Lin Shi, Zonglin He, Zonglin He, Jiasheng Wang, Jiasheng Wang, Jiecun Long, Jiecun Long, Yishun Zeng, Yishun Zeng, Qiong Gong, Qiong Gong   +18 more
doaj   +1 more source

Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

PLoS ONE, 2014
Tumor immune tolerance can derive from the recruitment of suppressor cell population, including myeloid derived suppressor cells (MDSCs), able to inhibit T cells activity.
Cesarina Giallongo, Nunziatina Parrinello, Daniele Tibullo, Piera La Cava, Alessandra Romano, Annalisa Chiarenza, Ignazio Barbagallo, Giuseppe A Palumbo, Fabio Stagno, Paolo Vigneri, Francesco Di Raimondo   +10 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4(+) T cells [PDF]

, 2015
Evidence links chronic inflammation with cancer, but cellular mechanisms involved in this process remain unclear. We have demonstrated that in humans, inflammatory conditions that predispose to development of skin and colon tumors are associated with ...
Anna Martner, Arthur, Balkwill, Bierie, Brandau, Brianna Lenox, Bromley, Castellino, Chen, Cheng, Cho, Coussens, Cuenca, Dalgleish, Daniel, Daniel, DeNardo, Dmitry Gabrilovich, Dyer, Dyson, Ehrchen, Esteban Celis, Feng, Fridlender, Fujita, Gabrilovich, Gabrilovich, Gabrilovich, Gasche, Gebhardt, George Malietzis, Girardi, Gui Han Lee, Güngör, Hagemann, He, Heidenreich, Henri, Hofseth, Huang, Humble, Ichikawa, John Seykora, Kim, Koebel, Källberg, Laxminarasimha Donthireddy, Leder, Le’Negrate, Manitz, Markowitz, Marnett, McNeill, Morgan Moorghen, Myrna L. Ortiz, Nagaraj, Newcomb, Noreen Luetteke, Ortiz, Peranzoni, Schlecker, Schmid, Shimizu, Sica, Sinha, Sorenson, Sridevi Mony, Srivastava, Stella C. Knight, Talmadge, Tepper, Thomas Condamine, Vinit Kumar, Wang, Xiao, Youn, Zhao   +76 more
core   +2 more sources

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

Journal of Hepatocellular Carcinoma, 2019
Li-Chun Lu,1–3 Chun-Jung Chang,1,2 Chih-Hung Hsu1–31Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; 2Departments of Oncology, National Taiwan University Hospital, Taipei, Taiwan; 3Department of ...
Lu LC, Chang CJ, Hsu CH
doaj  

AN UPDATE REVIEW ON IMMUNOSUPPRESSIVE CELLS; MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN CANCERS

مجلة الجامعة الأسمرية, 2020
Myeloid derived suppressor cells (MDSCs) are heterogeneous subsets of  immune cells and they function to inhibit host T cells activation leading  to  tumour  growth.  Currently,  the  majority  of  studies  support  key  contributions  of  MDSCs  to  tumour  progression  via  direct  mechanisms  immune   mediated   and   indirect   mechanism   which ...
openaire   +1 more source

Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis

Advanced Science, EarlyView.
FAK signaling drives chemoresistance and tumor evolution in pancreatic ductal adenocarcinoma. The FAK inhibitor IN10018 restores gemcitabine sensitivity by inducing SLC7A11‐mediated ferroptosis through the PI3K‐Akt pathway and remodeling the tumor microenvironment, reducing mesenchymal components while enhancing CD8+ T‐cell infiltration in preclinical ...
Yingjin Wang, Hui Yang, Baoyuan Zhang, Yongsu Ma, Kuangen Zhang, Peng Wang, Jiapeng Yang, Zaiqi Wang, Rong Liu, Xiaodong Tian, Ning Zhang, Yinmo Yang   +11 more
wiley   +1 more source

Neutrophils in cancer: neutral no more [PDF]

, 2016
Neutrophils are indispensable antagonists of microbial infection and facilitators of wound healing. In the cancer setting, a newfound appreciation for neutrophils has come into view.
A Blaisdell, A Carus, A Görgens, A Hasenberg, A Kohler, A Mantovani, A Sparmann, A Stoppacciaro, A Swierczak, A Warnatsch, AD Friedman, AD Panopoulos, AJ Casbon, AJ Gentles, AJ Templeton, AK Mankan, AM Houghton, AM Wengner, AP Tittel, AS Chung, B Ruffell, BK Popivanova, BT Suratt, BZ Qian, C Cheretakis, C Gordy, C Martin, CF Wu, CH Ries, CL Semerad, CL Semerad, D Di Mitri, D Marvel, D Metcalf, D Zhang, DI Gabrilovich, DJ Cua, DR Welch, E Elinav, EB Eruslanov, EI Deryugina, EM Bekes, F Chen, F Colotta, F Kuonen, F Liu, F Liu, F Rosenbauer, F Shojaei, F Shojaei, F Shojaei, F Shojaei, G Molineux, G Wang, GJ Guthrie, GJ Lieschke, GO Ahn, H Hirai, H Ji, H Katoh, H Nozawa, H Takahashi, H Tazawa, HH Yan, HK Jensen, HK Kim, HL Rao, HS Deshmukh, I Mishalian, I Petit, J Adolfsson, J Cools-Lartigue, J Crawford, J Jablonska, J Jiao, J Mei, J Pillay, J Pillay, J Pillay, J Sceneay, JC Pahler, JD Spicer, JD Waight, JD Waight, JF Seymour, JI Youn, JI Youn, JL Granick, JL Guerriero, JM Daley, JM Petty, JP Levesque, JT Dancey, JT Erler, JY Sagiv, K Fiedler, K Kersten, K Kim, K Shang, K Shitara, K Tomihara, KA Charles, Karin E. de Visser, KE De Visser, KH Steinbach, KJ Eash, KJ Eash, L Benevides, L Deng, L Gong, L Strauss, L Yang, L Yang, LA Pekarek, LB Rivera, LJ Bayne, LM Coussens, LP Seung, M Bodogai, M Bruchard, M Di Maio, M Elkabets, M Hager, M Ishikawa, M Kowanetz, M Papaspyridonos, M Santoni, M Van Egmond, M Wislez, MA Lopez-Lago, MA Postow, MA Stark, Max D. Wellenstein, MF Denny, MG Manz, MH Kim, MK Richards, MK Srivastava, MP Keane, MT O'Toole, N Antonio, N Borregaard, N Borregaard, P Andreu, P Ehrlich, P Schwarzenberger, P Wu, PC Burdon, PC Vincent, PJ Murray, Q Ma, R Bertini, R Catena, R Noy, RA Caruso, RA Droeser, RN Kaplan, S Acharyya, S Basu, S Dogan, S Hiratsuka, S Tazzyman, S Tazzyman, S Tu, SB Coffelt, SB Coffelt, SB Forlow, Seth B. Coffelt, SH Chang, SH Saverymuttu, SI Rennard, SJ Huh, SJ Moghaddam, SK Bunt, SK Wculek, SL Gaffen, SL Highfill, T Bald, T El Rayes, T Jamieson, T Kitamura, T Lämmermann, T Tak, T Voloshin, T Yamanaka, TE Sutherland, TO Jensen, V Cortez-Retamozo, V Finisguerra, VT Phan, WJ McKinstry, X Qu, X Song, XD Yang, Y Carmi, Y Han, Y Ma, Y Pang, Y Pylayeva-Gupta, Y Sawanobori, Y Tsuda, Y Ueda, Y Ueda, Z Granot, Z Li, ZG Fridlender   +205 more
core   +1 more source